SCAI and the European Society of Cardiology recently added iFR to their guidelines.

The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold standard for assessing the hemodynamic significance of coronary lesions to determine if they should be revascularized or treated medically. Despite being a part of the guidelines and clinician evidence clearly showing the benefit to using FFR, it is still not used in many patients.This is partly due to increased procedure costs from the wires, added procedural time and the use of adenosine as a stressor agent, which can be uncomfortable for patients.

Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers. These are the late-breaking findings presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, and published in the New England Journal of Medicine.

Biotronik announced it is now the exclusive U.S. distributor for the MoMe Kardia external cardiac diagnostic monitor from digital health company InfoBionic. The device benefits patients suspected of experiencing cardiac arrhythmias.

The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late-breaking results from the ARRIVE study. Results from ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, with simultaneous publication in The Lancet.1

Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD) in diabetes mellitus (DM) patients, a patient population in which PAD prevalence has traditionally been difficult to assess. Researchers believe these findings, presented at the 2018 European Society of Cardiology (ESC) Congress, Aug. 25-28 in Munich, Germany, could lead to early identification of PAD and improve patient clinical outcomes, as well as prevent patients without PAD from undergoing unnecessary, expensive and invasive tests.

The Zoll LifeVest wearable defibrillator system was evaluated in the late-breaking VEST Trial presented at ACC 2018 earlier this year. A review article on the results was the No. 1 most viewed article in July and August.

September 4, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of August 2018. This is based on website analytics of the month’s 192,631 pageviews in August:

1. Diving Deeper Into the Results of the VEST Trial Using Wearable Defibrillators

International Symposium on Ventricular Arrhythmias

Philips announced it has acquired Xhale Assurance Inc., a U.S.-based scale-up company developing and commercializing next-generation sensor technologies. Xhale Assurance’s disposable pulse oximetry sensor is placed on the wing (ala) of the nose, and can reliably measure and transmit a patient’s heart rate and blood oxygenation under low-perfusion conditions that are challenging for conventional fingertip pulse oximetry sensors. Philips said this technology will broaden and differentiate its existing portfolio of oxygen saturation monitoring solutions and allow the company to expand into a currently underserved clinical segment. Financial details of the transaction were not disclosed.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now